EUR/USD 1.17346
-0.042%
Gold 4699.98
-0.321%
Oil 97.096
-1.637%
USD/JPY 157.716
0.068%
GBP/USD 1.35344
-0.038%
GBP/JPY 213.464
0.034%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Samsung Electronics rose 1.3% in the afternoon, lagging behind the broader market; SK Hynix shares rose 7%.The European-Mediterranean Seismological Centre reported that a 4.3-magnitude earthquake struck off the coast of Chiapas, Mexico, at 12:05:41 Beijing time, with a focal depth of 15 kilometers.On May 13th, at the Create2026 Baidu AI Developer Conference, Shen Dou, Executive Vice President of Baidu Group and President of Baidu Smart Cloud Business Group, revealed that the Kunlun Chip P800 has completed large-scale verification, and multiple 10,000-card clusters have been delivered since 2025. Furthermore, on the Kunlun Chips domestically produced clusters, training on the important version 5.1 of Wenxin has been successfully completed, achieving an effective training rate of 97% for the entire cluster. The linear scalability of the 10,000-card cluster exceeds 85%, meeting the requirements of cutting-edge large-scale model training for computational accuracy, operator stability, framework adaptation, and long-term operation. In addition, the Tianchi 256-card supernode based on the Kunlun Chip was lit up last month and will be officially launched in June.On May 13th, Dirk Pant, the Minister of Economic Affairs of Saxony, Germany, stated that as the German automotive industry faces pressure to transform, a more pragmatic approach should be taken to cooperation with Chinese automakers. He suggested introducing Chinese partners to participate in the states automotive plants through joint ventures and other means. Pant also noted that the global automotive industry landscape is undergoing profound changes, with China becoming an innovation driver and industry leader in areas such as electric vehicles and battery technology. Chinese automakers and joint ventures have already begun local production in several European countries. "Anyone who hopes to secure the future of the Saxon and even the German automotive industry cannot ignore this reality," he said.On May 13, Miniso (09896.HK) announced on the Hong Kong Stock Exchange that, based on a preliminary review and assessment of the unaudited consolidated management accounts for the quarter ended March 31, 2026, the Group expects to record revenue of approximately RMB5,678 million to RMB5,728 million, representing an increase of approximately 28% to 29% year-on-year; operating profit of approximately RMB1,511 million to RMB1,531 million, representing an increase of approximately 113% to 116% year-on-year; and profit for the period of approximately RMB1,228 million to RMB1,248 million, representing an increase of approximately 195% to 200% year-on-year.

AstraZeneca's Breast Cancer Medication Could Be Used More Widely After New Results

Charlie Brooks

Jun 06, 2022 10:56

3.png


According to data published on Sunday, AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Enhertu increased survival by more than six months in patients with advanced breast cancer compared to usual chemotherapy.


The data, which was presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, might open a big, new multibillion-dollar patient group for the medicine that received U.S. approval late in 2019 for the 15 percent of breast cancer patients with HER2-positive illness.


Over 550 patients with so-called HER2-low breast cancer - the majority with hormone-sensitive tumors - whose disease had progressed and who had completed at least one round of chemotherapy are participating in the ongoing phase III research.


The interim analysis revealed that Enhertu increased survival by an extra 6,4 months in hormone-sensitive tumor patients. The group had a median survival rate of 23.9 months, compared to 17.5 months for chemotherapy patients.


In the small sample of patients with hormone-resistant tumors, Enhertu improved survival by 6.3 months.


David Fredrickson, executive vice president of AstraZeneca's oncology unit, expressed surprise to Reuters that the improvement in overall survival was obvious even at the interim analysis point.


This provides a great deal of assurance that the benefit we are observing here is genuine.


The prognosis for individuals with advanced HER2-positive breast cancer has been vastly improved by a variety of targeted therapy. More than half of women whose breast cancer has progressed to other organs and express little or no HER2 have restricted therapeutic options; this is known as HER2-low status.


It was statistically significant that hormone-sensitive patients who got Enhertu had a progression-free survival (PFS) of 10.1 months on average, compared to 5.4 months for chemotherapy.


Enhertu more than doubled the PFS for hormone-insensitive individuals, from 2.9 months with chemotherapy to 6.6 months with Enhertu.


AstraZeneca is in talks with regulators worldwide regarding authorisation for the HER2-low population. Analysts at Jefferies predicted last month that annual global peak sales of Enhertu for these patients would reach $2.5 billion, and around $6.6 billion for all indications.


There are safety issues with the medicine, which is provided by intravenous infusion. It has been associated with interstitial lung disease, a form of lung scarring (ILD). In the trial, 45 Enhertu patients developed varied degrees of ILD, compared to one patient in the chemotherapy group.


Enhertu is part of a therapeutic class known as antibody drug conjugates (ADC), which are designed antibodies that bind to cancer cells and release cell-killing chemicals.


A study showed that it lowered the risk of disease progression or death by 72% when compared to Roche's Kadcyla, the standard treatment. It was approved as a second-line treatment option last month.


Enhertu is being studied for usage in breast cancer's earliest stages, as well as lung and colorectal malignancies. It has been approved for HER2-positive stomach cancer.


Reuters quoted Tara Hansen, a consultant at Informa Pharma Custom Intelligence, as saying, "As far as breast cancer is concerned, I'm rather certain that Enhertu will finish revolutionizing the therapy paradigm over the next five years."


In 2021, Enhertu generated $214 million in revenue. Three years ago, AstraZeneca acquired partial rights to the Daiichi Sankyo chemical in a deal valued up to $6.9 billion.


Suggestion